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Objectives: Favipiravir has discrepant activity against SARS-CoV-2 in vitro, concerns about teratogenicity and pill
burden, and an unknown optimal dose. This analysis used available data to simulate the intracellular pharma-
cokinetics of the favipiravir active metabolite [favipiravir ribofuranosyl-50-triphosphate (FAVI-RTP)].
Methods: Published in vitro data for intracellular production and elimination of FAVI-RTP in Madin–Darby canine
kidney cells were fitted with a mathematical model describing the time course of intracellular FAVI-RTP as a
function of favipiravir concentration. Parameter estimates were then combined with a published population
pharmacokinetic model in Chinese patients to predict human intracellular FAVI-RTP. In vitro FAVI-RTP data were
adequately described as a function of concentrations with an empirical model, noting simplification and consoli-
dation of various processes and several assumptions.
Results: Parameter estimates from fittings to in vitro data predict a flatter dynamic range of peak to trough for
intracellular FAVI-RTP (peak to trough ratio of 1 to 1) when driven by a predicted free plasma concentration
profile, compared with the plasma profile of parent favipiravir (ratio of 2 to 1). This approach has important
assumptions, but indicates that, despite rapid clearance of the parent from plasma, sufficient intracellular
FAVI-RTP may be maintained across the dosing interval because of its long intracellular half-life.
Conclusions: Population mean intracellular FAVI-RTP concentrations are estimated to be maintained above the Km
for the SARS-CoV-2 polymerase for 9 days with a 1200 mg twice-daily regimen (following a 1600 mg twice-daily load-
ing dose on day 1). Further evaluation of favipiravir as part of antiviral combinations for SARS-CoV-2 is warranted.
Introduction
The urgent global public health threat posed by COVID-19 has led
the global scientific community to rigorously explore opportunities
for repurposing existing medicines based upon either demonstra-
tion of auspicious antiviral activity against SARS-CoV-2 or a plaus-
ible mechanistic basis for anti-inflammatory/immunomodulatory
activity. If sufficiently potent antiviral agents can be identified,
there is potentially significant opportunity for deployment either
as prophylaxis or in early infection to prevent development of
severe disease. The role of antivirals in later stages of COVID-19 is
less clear, but cannot be rigorously assessed until sufficiently po-
tent antiviral drug combinations become available. Several groups
have highlighted the importance of considering the fundamental
principles of clinical pharmacology when selecting candidates
for investigation as antiviral agents,1–3 including a nuanced
understanding of the principles of plasma protein binding.4 For
most successful antiviral drugs developed to date, a key principle is
that plasma drug concentrations be maintained above in vitro-
defined target concentrations (EC90 or protein binding-adjusted
EC90 where available) for the duration of the dosing interval. It
should be noted that neither the pharmacokinetic-pharmacody-
namic relationship nor the pharmacokinetic parameters that
best serve as surrogates for efficacy are yet understood for any
SARS-CoV-2 antiviral drug. However, where the drug target resides
intracellularly, and generation of an intracellular active metabolite
is a prerequisite to unmask the pharmacophore, a more thorough
understanding of the intracellular pharmacokinetics is required to
rationalize doses required to maintain antiviral activity. For ex-
ample, nucleoside-based drugs or prodrugs require intracellular
phosphorylation by a cascade of host proteins, to generate
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tri-phosphorylated metabolites that exert the activity on the viral
polymerase.5,6 Indeed, antiviral nucleoside analogues for HIV (e.g.
tenofovir alafenamide), HCV (sofosbuvir) and several of the repur-
posing opportunities for SARS-CoV-2 (e.g. remdesivir) have active
triphosphate metabolites with intracellular half-lives much longer
than the parent drug in plasma.7–9 Therefore, for many nucleo-
sides being explored for SARS-CoV-2 (including favipiravir and
molnupiravir), the activity may be maintained across the dosing
interval, despite plasma concentrations of the parent dropping
below the EC90 at trough concentration (Ctrough).
Favipiravir is approved for influenza in Japan, but not elsewhere,
and has been intensively studied as a potential antiviral interven-
tion for several other RNA viruses; most recently SARS-CoV-2. For
several reasons, considerable uncertainty exists about the suitabil-
ity of favipiravir as a COVID-19 intervention. Concerns about
teratogenicity and high pill burden may limit widespread uptake of
the drug during early infection, particularly in the absence of con-
comitant contraceptive use in women of child-bearing age.10
Furthermore, in vitro studies of favipiravir in Vero-E6 cells infected
with SARS-CoV-2 have yielded inconsistent findings11–14 and low
potency (EC90 = 159 mM; 24.9mg/mL) has been described in those
studies that have shown activity.14 By comparison the EC50 of
favipiravir against influenza A has an approximate range of 0.03 to
0.94mg/mL.10,15 Favipiravir plasma concentrations also appear to
diminish, the longer that patients receive the medicine,10 and
studies in severe COVID-19 disease have shown that plasma expo-
sures are almost entirely abolished.16 Despite the uncertainty
and potential limitations, favipiravir has been demonstrated to
exert antiviral activity against SARS-CoV-2 in the Syrian Golden
Hamster model17 and, despite extremely high doses (1000 mg/kg
intraperitoneally), Ctrough values in this model were similar to those
achieved in human studies of influenza (4.4mg/mL in hamsters
versus 3.8mg/mL day 10 trough in humans).17,18 Cell-free models
have also demonstrated the ability of the intracellular metabolite
favipiravir ribofuranosyl-50-triphosphate (FAVI-RTP) to directly
inhibit the SARS-CoV-2 polymerase.19
The purpose of this work was to model, from published
plasma pharmacokinetic profiles, the likely concentrations of the
intracellular active moiety (FAVI-RTP) and evaluate whether puta-
tive target concentrations necessary to inhibit SARS-CoV-2 can be
pharmacologically attained in humans.
Methods
Prior in vitro data
Data for the intracellular formation and catabolism of intracellular FAVI-
RTP in Madin–Darby canine kidney (MDCK) cells following incubation with
parent favipiravir were digitized from previously published work of Smee et
al.20 In vitro phosphorylation of favipiravir has been assessed in various cell
lines21 and the production of FAVI-RTP in MDCK cells shown by Smee et al.20
is of similar magnitude to that shown in HeLa and Vero cells.21 The data of
Smee et al.,20 however, characterize a full time course of the production
and elimination of the FAVI-RTP metabolite rendering it the most suitable
for this pharmacokinetic modelling exercise.
Briefly, the in vitro experiments carried out by Smee et al.20 involved in-
cubation of confluent layers of MDCK cells in T-25 flasks with media con-
taining favipiravir at 32, 100, 320 or 1000mM for varying durations. Smee et
al.20 included 10% FBS in media and plasma protein binding of favipiravir is
relatively low in humans (54%).10 Therefore, given that the protein
concentration in the medium was low in these incubations, it was assumed
that the nominal in vitro media concentrations of favipiravir for the incuba-
tions equated to the free drug concentrations.
At given timepoints, medium was removed, cells were washed and
lysed, and FAVI-RTP was quantified in the lysate using HPLC with UV detec-
tion. For catabolism/elimination experiments, MDCK cells were incubated
with media containing favipiravir at the specified concentrations for 24 h to
allow production and accumulation of FAVI-RTP, before medium was
removed and replaced with favipiravir-free medium. Incubation then con-
tinued for a series of timepoints; at these timepoints medium was removed
and cell lysate was assayed for FAVI-RTP. Smee et al.20 present their FAVI-
RTP quantification in normalized units of pmol/106 cells according to the
cell counts of the incubations, which was taken to represent the normalized
intracellular amount of FAVI-RTP. In this work, a value provided by
Bitterman and Goss22 for the volume of an MDCK cell of 2.08 pL was then
used to convert the FAVI-RTP quantification of Smee et al.20 into units of
pmol/(106 pL) = pmol/mL =mM.
Modelling of in vitro data
The data for intracellular production and elimination of FAVI-RTP were fit-
ted with a mathematical model in the R programming environment (v
4.0.3)23 to describe and parameterize the observed data as a function of
the incubation media concentrations and time. This fitting made use of the
Pracma library24 and lsqnonlin function for non-linear regression.
Data for intracellular production (in the presence of favipiravir-contain-
ing media) and elimination of FAVI-RTP (on removal of favipiravir-contain-
ing media after a 24 h incubation and replacement with blank media) were
combined into single time courses for each medium concentration, to then
be described with the following ordinary differential (rate) equation math-
ematical model (schematic provided in Figure 1a):
Equation 1 :
d½FAVI-RTPcell
dt
¼ kin  ½favipiravirmedia
kout  ½FAVI-RTPcell
where [] denotes concentration. The initial condition for [FAVI-RTP]cell is set
to zero at time zero and [favipiravir]media switched to equal zero at the 24 h
timepoint to end the production rate of FAVI-RTP and allow only the elimin-
ation rate to describe observed, declining concentrations from that time
forward. The parameter kin has units of time
#1 and simultaneously
describes net influx/diffusion of parent favipiravir from media into the cell
and its (net) subsequent conversion into FAVI-RTP. The use of kin therefore
simplifies a more detailed description of favipiravir net influx into cells and
conversion into FAVI-RTP into an empirical first-order process dependent
on media concentration of favipiravir, to enable use of the information in
the available data, where parent favipiravir itself is not quantified.
Smee et al.20 do not explicitly quote the volume of media used in their
incubations, but given the T-25 flasks used, a media volume of 5–10 mL
could be expected. Across the lowest to highest favipiravir media concen-
trations in the data (32 and 1000mM), this therefore translates to a range of
0.16 to 10mmol favipiravir present in the incubations at time = 0. The max-
imum amount of intracellular FAVI-RTP produced after 24 h in the 1000mM
incubation was 332 pmol/106 cells; with incubations declared to contain
approximately 7%106 cells on average, this gives a maximum total
amount of 2324 pmol = 2.3 nmol of FAVI-RTP converted from favipiravir in
1:1 stoichiometry, which is1% conversion of the total amount of favipira-
vir available in the 1000mM incubation at the start (with similar calculations
demonstrable at the other media concentrations). Therefore the [favipira-
vir]media term in Equation 1 can be considered approximately constant for a
given time course dataset of incubations at a specified favipiravir concen-
tration. In turn, this renders Equation 1 equivalent to a zero-order constant
input model with first-order elimination and with the zero-order input being
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switched off at 24 h when media containing favipiravir was replaced with
blank media.
In vivo intracellular simulations
The model and parameter estimates from the fitting to in vitro intracellular
data, describing intracellular FAVI-RTP concentrations as a function of the
media incubation concentrations, were then taken forward and combined
with a population pharmacokinetic model for plasma exposure for favipira-
vir described by Wang et al.18 in a Chinese population receiving the drug for
influenza, substituting the media incubation concentration driving the
intracellular FAVI-RTP production rate with the free plasma concentration
predicted by the population pharmacokinetic model. This provided a pro-
spective simulation of in vivo intracellular concentrations of FAVI-RTP
(assuming cells of similar disposition to MDCK cells) as a function of in vivo
plasma exposure.
The population pharmacokinetic model of Wang et al.18 is a one-com-
partment pharmacokinetic disposition model with first-order absorption.
Therefore, the equations for the model for in vivo intracellular simulations
were as follows (schematic provided in Figure 1b):
Equation 2 :
dAFavidepot
dt
¼ ka  AFavidepot
Equation 3 :
d½favipiravirplasma
dt
¼ ðka  AFavidepot
– CL ½favipiravirplasmaÞ=V
Equation 4 :
d½FAVI-RTPcell
dt
¼ ðkin  ½favipiravirplasma  FuplasmaÞ
 kout  ½FAVI-RTPcell
where [] denotes concentration, CL and V are apparent values CL/F and V/F,
and kin and kout used values derived from the in vitro model fitting. The
Wang et al.18 model also incorporated a time-dependent effect on CL, rep-
resentative of favipiravir autoinduction of its own elimination, where:
Equation 5: CL ¼ CLday0  ð1þ 0:0614 days of dosingÞ
The model assumes a minimal proportion of the total mass balance of
favipiravir transfers in from the plasma before conversion into the
intracellular FAVI-RTP (similar to how the in vitro model assumes a constant
[favipiravir]media) and was therefore similar in some respects to a pharma-
cokinetic-pharmacodynamic effect compartment model.
Pharmacokinetic parameter population inter-individual variabilities esti-
mated by Wang et al.18 were used to simulate a population of 1000 sets of
pharmacokinetic parameters and their resultant predicted [favipiravir]-
plasma and [FAVI-RTP]cell profiles, from which 90% prediction interval profile
envelopes were calculated. No population distribution of body weight was
incorporated into this simulation, which is equivalent therefore to assuming
each simulated subject had a body weight of 70 kg according to the Wang
et al.18 population pharmacokinetic model. No inter-individual variability in
the kin or kout parameters was available or assumed. Parameter values
used, and their inter-individual variabilities, quoted from the population
pharmacokinetic model of Wang et al.18 are provided in Table 1, with
Fuplasma set at 0.46.
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Results
Modelling of in vitro data
Data from the observed [FAVI-RTP]cell from Smee et al.
20 at the
four media concentrations investigated, overlaid with the model
fittings, are given in Figure 2, with parameter estimates and associ-
ated % relative standard errors in Table 2. The model was deemed
to provide a satisfactory description of the observed data with ac-
ceptable precision of parameter estimates. However, it should be
Figure 1. Schematics of mathematical models for favipiravir and intracellular FAVI-RTP kinetics as applied to in vitro data and used for in vivo simula-
tions. [] denotes concentration.
Table 1. Summary of favipiravir population pharmacokinetic model par-
ameter estimates used for simulation, from Wang et al.18
Parameter Est.
Inter-individual
variance (x2, log
parameters)
F (apparent, fractional) 1 (fixed) 0.0921
ka (h
#1) 1.5 1.05
CL/F (L/h) 2.96 0.274
V/F (L) 37.1 0.128
Time-dependent effect on
CL/F (% per day)
6.14 –
Inter-individual covariance
for ka and V/F (x
2
kax2V/F)
– 0.23
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noted that kin values were not observed to be constant across the
media incubation concentrations. A plot of kin versus [favipiravir]-
media (the latter on a log scale) is provided in Figure 3, indicating
that some form of saturable relationship is most likely present,
which may require an Emax-type model to be accurately described
over the full range of media concentrations. However, with data
available at only four media concentrations there was insufficient
information to adequately fit such a saturable model. A log-linear
model has therefore been fitted instead to the log-linear portion of
the kin versus [favipiravir]media curve ([favipiravir]media ranges from
32 to 320mM, which also encompasses a typical range of in vivo
plasma concentrations under standard human dosing regimens)
and is overlaid in Figure 3, where:
Equation 6: kin ¼ lnð½favipiravirmediaÞ  kinslope þ kinintercept
The values of kin_slope and kin_intercept were then taken forward to
the in vivo simulations instead of a mean value of kin, or the value
from one [favipiravir]media fitting alone, and were used via
Equation 6 during simulations to calculate the value of kin required
for any free plasma concentration at any given time as an input
parameter value for Equation 4. kout estimates from fittings were
consistent at the four in vitro [favipiravir]media concentrations.
Therefore, the mean of the four estimates (0.108 h#1) was taken
as the input value for simulations using Equation 4.
In vivo intracellular simulations
Simulations of predicted in vivo plasma and intracellular exposures
for favipiravir and FAVI-RTP are shown in Figure 4(a) for a dosing
Figure 2. Pharmacokinetic model fittings to in vitro time courses of [FAVI-RTP]intracellular generated by Smee et al.
20 in MDCK monolayers.
Table 2. Parameter estimates from in vitro pharmacokinetic model
fittings
[Favipiravir]media kin (h
#1) kout (h
#1)
1000mM
est. 0.020 0.126
%RSE 13.9 11.4
320mM
est. 0.021 0.089
%RSE 14.7 15.6
100mM
est. 0.033 0.112
%RSE 12.0 10.7
32 mM
est. 0.048 0.105
%RSE 15.3 14.3
%RSE, % relative standard error.
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regimen of 1600 mg twice daily as a loading dose on day 1 fol-
lowed by 800 mg twice-daily maintenance dosing for 9 further
days. Simulations of predicted in vivo plasma and intracellular
exposures for favipiravir and FAVI-RTP are shown in Figure 4(b) for
a dosing regimen of 1600 mg twice daily as a loading dose on day
1 followed by 1200 mg twice-daily maintenance dosing for 9 fur-
ther days. In both cases, reference to the Km (Michaelis–Menten
constant) for FAVI-RTP against the SARS-CoV-2 RNA-dependent
RNA polymerase (RdRp) enzyme19 is overlaid. The plasma target
exposure based on the in vitro EC90 of favipiravir of 159mM against
SARS-CoV-214 is also shown, but should be interpreted with caution
owing to the lack of clarity in in vitro free drug concentrations and
whether human plasma binding is high or low affinity.
Discussion
While studies in the Syrian Golden Hamster have demonstrated
the effectiveness of favipiravir against SARS-CoV-2, in vitro activity
data generated in the Vero-E6 cell model have questioned the util-
ity of the molecule when the derived target concentrations
are compared with the pharmacokinetics after administration to
humans. Ultimately, robustly designed and executed clinical trials
will be required to determine the utility of favipiravir for SARS-CoV-
2, but understanding the mechanisms that underpin the clinical
pharmacology is important to understand the plausibility for
evaluation, which should underpin the selection of candidates for
clinical evaluation. Furthermore, an a priori understanding of likeli-
hood of success for future candidates can only evolve from a thor-
ough understanding of the pharmacokinetic-pharmacodynamic
rules of engagement for SARS-CoV-2, which currently do not exist.
Antiviral drugs have only thus far been unequivocally successful
for other viruses when given in combination and the requirement
of combinations to improve potency and/or stem emergence of
resistance requires careful consideration so as not to obviate
the lessons that should be learned from other pathogens.
Notwithstanding, favipiravir has been evaluated at several differ-
ent doses and schedules in numerous clinical trials globally, with
mixed outcomes.25–27 As of 29 December 2020, a total of 44 trials
were listed on clinicaltrials.gov aiming to evaluate favipiravir,
predominantly as a monotherapy (with some exceptions) and in
various-use cases.
The current analysis aimed to apply a pharmacokinetic model-
ling approach to better understand the potential efficacy of favipir-
avir for SARS-CoV-2 at doses readily achievable in humans. The
simulations synthesized available data for intracellular kinetics of
FAVI-RTP in MDCK cells, plasma pharmacokinetics in a Chinese pa-
tient population, in vitro-derived antiviral activity data (EC90) and
cell-free inhibition data for FAVI-RTP against the SARS-CoV-2 RNA
polymerase. Importantly, this modelling approach indicates that,
despite rapid clearance of the parent drug from plasma, the peak
Figure 3. Log-linear fitting to kin as a function of media favipiravir concentration.
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Figure 4. Favipiravir plasma and intracellular FAVI-RTP concentration predictions based on the population pharmacokinetic model of Wang et al.18
combined with in vitro intracellular pharmacokinetic modelling, for a dosing regimen of 1600 mg twice daily as a loading dose on day 1 followed by
800 mg twice-daily maintenance dosing for 9 further days (a) or 1600 mg twice daily as a loading dose on day 1 followed by 1200 mg twice-daily
maintenance dosing for 9 further days (b). The dashed red line represents the previously published Km for inhibition of SARS-CoV-2 polymerase by
FAVI-RTP, 19 the dotted red line represents Ctrough plasma concentrations of favipiravir following a 1000 mg/kg/day dose in hamsters
17 and the solid
red line represents the in vitro EC90 of favipiravir against SARS-CoV-2 in Vero-E6 cells.
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to trough variability in intracellular FAVI-RTP is such that activity
may be maintained across the dosing interval because of the long
intracellular half-life. The simulations indicate that the population
mean intracellular FAVI-RTP concentrations will be maintained
above the FAVI-RTP Km for the SARS-CoV-2 polymerase for 3 days
during an 800 mg twice-daily dosing regimen and 9 days during a
1200 mg twice-daily dosing regimen (both regimens including a
1600 mg twice-daily loading dose on day 1). The ratio of peak to
trough concentrations in plasma on the second day of dosing for
both 800 and 1200 mg maintenance dosing regimens is approxi-
mately 2.3 to 1, while for intracellular FAVI-RTP the peak to trough
ratio is a flatter 1.1 to 1. Importantly, the flatter intracellular phar-
macokinetic profile of the phosphorylated form of favipiravir is in
keeping with observations for other antiviral nucleoside/nucleotide
analogues such as tenofovir-diphosphate,28,29 which underpins
the efficacy of these drugs for other viruses.
The current approach has several important limitations that
should be recognized. Favipiravir pharmacokinetic exposures have
been demonstrated to be lower in American and African patients
than in Chinese patients30 and so the simulations may not
be widely applicable across different ethnicities. This potential
inter-ethnic difference in favipiravir exposure may reflect a wider
variability in favipiravir pharmacokinetics that may become better
characterized as further trials with it are carried out. Simulations
here should be considered in the specific context therefore of the
Wang et al.18 population pharmacokinetic dataset and model
that informed the favipiravir pharmacokinetic parameters for this
exercise.
The modelling approach applied a direct in vitro to in vivo
extrapolation of kin and this should be considered as a major
assumption as it directly presumes the in vitro favipiravirmedia
concentration is representative of the free plasma concentration
as derived from the pharmacokinetic model and that the umbrella
kin parameter, which consolidates various underlying uptake and
conversion processes, is directly translatable. Importantly, the
presented intracellular predictions are specific to data generated
on intracellular kinetics in MDCK cells. Therefore, the accuracy of
the intracellular FAVI-RTP concentrations will be dependent upon
the similarity of relevant human in vivo cells in terms of the in vitro
uptake/elimination as well as the rate and extent of metabolic ac-
tivation of favipiravir to its triphosphorylated active form. Although
in vivo intracellular phosphorylation of favipiravir is yet to be well
characterized in the literature, favipiravir intracellular phosphoryl-
ation to FAVI-RTP of a similar magnitude to that seen by Smee et
al.20 in MDCK cells has also been demonstrated in vitro in other cell
lines, including the Vero cell line.21 Given that the correlation be-
tween in vitro and in vivo intracellular phosphorylation has been
demonstrated in Vero cells for various other NRTIs31 and that
favipiravir in vitro phosphorylation is similar in MDCK and Vero cells,
by extension, it remains reasonable that in vitro phosphorylation in
MDCK cells remains an indicator of intracellular phosphorylation
in vivo. It would be a reasonable avenue for future work to investi-
gate validation of the in vitro intracellular modelling and extra-
polation approach applied here with other nucleoside analogues
where suitable intracellular in vitro and in vivo data both exist.
Intracellular predictions are limited further in this work in that
there are no data with which to model the inter-patient variability
in the intracellular uptake or conversion into FAVI-RTP and so intra-
cellular concentration variability shown in Figure 3 is only derived
from intracellular variability in plasma exposure. Finally, the
intracellular prediction is driven by the estimated free plasma
concentration, whereas in vivo it is possible local tissue free drug
concentrations at the target organ for which there are no available
data may be higher or lower than in plasma.
Despite these limitations, additional confidence in the predic-
tions comes from two important sources. Firstly, following the first
day of dosing, there is generally good agreement between the
point at which the plasma favipiravir concentrations intersect the
in vitro-derived EC90 and the corresponding intracellular FAVI-RTP
value being close to its Km value derived separately in a cell-free
system with the SARS-CoV-2 polymerase (Figure 3). It should be
noted that no data are available with which to derive a protein-
adjusted EC90 value of favipiravir. Secondly, the clear activity of
favipiravir in the Syrian Golden Hamster model when Ctrough values
are similar to those in humans gives additional confidence in the
predictions.17
In summary, these simulations indicate that favipiravir
maintenance doses between 800 and 1200 mg twice daily may be
sufficient to provide therapeutic concentrations of the intracellular
FAVI-RTP metabolite across the dosing interval. Further evaluation
of favipiravir as an antiviral for SARS-CoV-2 appears to be war-
ranted and will provide additional clarity on its putative utility.
However, the recent emergence of variants of the virus requires
careful consideration of the drug resistance threat posed by using
repurposed agents as monotherapies, particularly when they are
likely not to be fully active in all patients. The polymerase, along
with the protease and spike, are likely to be extremely important
drug targets for new chemical entities and care should be taken
not to compromise their utility before the first-generation specific
SARS-CoV-2 antivirals emerge.
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